. Author manuscript; available in PMC: 2018 Jan 24.

Published in final edited form as: J Am Coll Cardiol. 2017 Jan 24;69(3):303–321. doi: 10.1016/j.jacc.2016.10.065

Table 1.

Baseline patient characteristics of the study population and the validation set: values are expressed as n (%), mean ± standard deviation.

(AF: atrial fibrillation; LA: left atrial; LVEF: left ventricular ejection fraction.)

	Study population (n=105)	Validation set (n=47)	p
Age (years), mean + SD	63 +11	58±11	0.0046
Male, n (%)	80 (76.2%)	35 (74%)	0.8191
AF type
Paroxysmal AF, n (%)	24 (22.8%)	9 (19,2%)	0,6
Non-paroxysmal AF, n (%)	81 (77,2%)	38(80,8%)	0,6
Maximum sustained AF duration (months), mean + SD	12.2 + 20	19.4±31.6	0.2457
Structural heart disease, n(%)	38 (36%)	14 (35%)	0.4665
Hypertension, %	48(45,7%)	20 (42,5%)	0.5217
Diabetes, %	13(12.4%)	5(10,6%)	0,5995
LA diameter (mm), mean + SD	45,6± 7,6	42,4±12,4	0,09
LVEF (%), median mean + SD	52 ± 11	54 ± 12	0,2082
Amiodarone before ablation, %	32%	NA
Spontaneous AF at the beginning of procedure (persistent and longstanding persistent AF only), n	65	NA